Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas
The demonstrated tolerability and efficacy of obrixtamig regimens, administered as step-up followed by target doses of 90-1,080 μg/kg (once weekly or once every 3 weeks), in patients with heavily pretreated DLL3-positive tumors support further exploration in SCLC, epNEC, and LCNEC-L.
Authors
- Edurne Arriola (ORCID: https://orcid.org/0000-0001-8960-7519)
- Miguel F. Sanmamed (ORCID: https://orcid.org/0000-0002-7295-6074)
- Juergen Wolf (ORCID: https://orcid.org/0000-0001-8833-8812)
- Daniel Morgensztern (ORCID: https://orcid.org/0000-0003-4349-2028)
- Martin Wermke (ORCID: https://orcid.org/0000-0002-4844-4087)
- Mohamed Bouzaggou
- Cyrus Sayehli
- Valentina Gambardella (ORCID: https://orcid.org/0000-0001-6081-8830)
- Olatunji B. Alese (ORCID: https://orcid.org/0000-0001-8079-4725)
- Xiaoyan Fang (ORCID: https://orcid.org/0000-0002-1893-8457)
- Matus Studeny
- Yasutoshi Kuboki (ORCID: https://orcid.org/0000-0003-3675-953X)
- Julia Bertulis (ORCID: https://orcid.org/0000-0002-4863-6003)
- Liza Cosca Villaruz (ORCID: https://orcid.org/0000-0001-7456-523X)
- Enriqueta Felip (ORCID: https://orcid.org/0000-0002-7620-0098)
Institutions
- Hebron University (PS)
- Boehringer Ingelheim (Germany) (DE)
- Emory University (US)
- Universitat de València (ES)
- Washington University in St. Louis (US)
- Centro de Investigación Biomédica en Red (ES)
- Universitätsklinikum Würzburg (DE)
- Vall d'Hebron Hospital Universitari (ES)
- UPMC Hillman Cancer Center (US)
- Clinica Universidad de Navarra (ES)
- Boehringer Ingelheim (France) (FR)
- National Cancer Center Hospital East (JP)
- Boehringer Ingelheim (China) (CN)
- University Hospital Cologne (DE)
- Hospital del Mar Research Institute (ES)
- INCLIVA Health Research Institute (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Technische Universität Dresden (DE)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1200/jco-25-00363
- Citations
- 13
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 13.59